These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29621897)

  • 1. Current and potential targets for drug design in the androgen receptor pathway for prostate cancer.
    Guddati AK
    Expert Opin Drug Discov; 2018 Jun; 13(6):489-496. PubMed ID: 29621897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
    Fujii S; Kagechika H
    Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J; Smith A; Ong M; de Bono JS
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor antagonists: a patent review (2008-2011).
    Mohler ML; Coss CC; Duke CB; Patil SA; Miller DD; Dalton JT
    Expert Opin Ther Pat; 2012 May; 22(5):541-65. PubMed ID: 22583332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
    Culig Z; Santer FR
    Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens in prostate cancer: A tale that never ends.
    Hou Z; Huang S; Li Z
    Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of prostate cancer by hormone-responsive G protein-coupled receptors.
    Wang W; Chen ZX; Guo DY; Tao YX
    Pharmacol Ther; 2018 Nov; 191():135-147. PubMed ID: 29909235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer.
    Singla N; Ghandour RA; Raj GV
    Expert Opin Investig Drugs; 2019 Mar; 28(3):249-259. PubMed ID: 30649971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
    Sakkiah S; Ng HW; Tong W; Hong H
    Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
    Mostaghel EA; Plymate SR; Montgomery B
    Clin Cancer Res; 2014 Feb; 20(4):791-8. PubMed ID: 24305618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?
    Hoffman-Censits J; Fu M
    Semin Oncol; 2013 Jun; 40(3):361-74. PubMed ID: 23806500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
    Chen Y; Clegg NJ; Scher HI
    Lancet Oncol; 2009 Oct; 10(10):981-91. PubMed ID: 19796750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.